Monoclonal antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
US6617118B2 · kind B2 · utility
16Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2001 |
| Grant date | Sep 9, 2003 |
| Priority date | — |
| Expiry date | Apr 13, 2021 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2430/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel anti-polyethylene glycol monoclonal antibody and its preparation are disclosed. Such an antibody can be used for determining polyethylene glycol concentration in vitro or accelerating the clearance of a polyethylene glycol containing compound from the blood circulation in the human body thereby reducing the toxicity associated with the polyethylene glycol containing conjugate. The antibody is particularly useful in cancer therapy where the therapeutic agent is selectively delivered to the tumor by increasing the tumor/blood ratio of the polyethylene glycol containing compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.